冠脉介入术后再狭窄药物治疗的临床研究进展

被引:4
作者
苏华科
宋耀明
机构
[1] 第三军医大学新桥医院全军心血管内科研究所
关键词
西洛他唑; 普罗布考; 再狭窄; 药物治疗;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
100201 [内科学];
摘要
经皮冠状动脉成形术(PTCA)已广泛应用于治疗有症状冠心病,但术后再狭窄的发生限制了其应用。冠脉内支架的应用使再狭窄率有所下降,但是再狭窄的防治仍然是一个新的、棘手的问题。以普罗布考和西洛他唑为代表的少数药物,临床试验证实其防治再狭窄作用显著,可望成为裸支架或药物洗脱支架重要辅助措施。本文综述再狭窄防治药物的临床研究进展,以期进一步了解再狭窄的防治途径。
引用
收藏
页码:155 / 156+159 +159
页数:3
相关论文
共 11 条
[1]
Pioglitazone reduces neointima volume after coronary stent implantation -: A randomized, placebo-controlled, double-blind trial in nondiabetic patients [J].
Marx, N ;
Wöhrle, J ;
Nusser, T ;
Walcher, D ;
Rinker, A ;
Hombach, V ;
Koenig, W ;
Höher, M .
CIRCULATION, 2005, 112 (18) :2792-2798
[2]
RACTS: A Prospective Randomized Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting: Long-Term Clinical and Angiographic Outcome.[J].Junbo Ge;Yaling Han;Hong Jiang;Baogui Sun;Jiyan Chen;Shuyang Zhang;Zhimin Du.Journal of Cardiovascular Pharmacology.2005, 2
[3]
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine [J].
Tanabe, Y ;
Ito, E ;
Nakagawa, I ;
Suzuki, K .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 78 (03) :285-291
[4]
Effects of cilostazol on angiographic restenosis after coronary stent placement [J].
Park, SW ;
Lee, CW ;
Kim, HS ;
Lee, NH ;
Nah, DY ;
Hong, MK ;
Kim, JJ ;
Park, SJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (05) :499-503
[5]
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty [J].
Tsuchikane, E ;
Fukuhara, A ;
Kobayashi, T ;
Kirino, M ;
Yamasaki, K ;
Kobayashi, T ;
Izumi, M ;
Otsuji, S ;
Tateyama, H ;
Sakurai, M ;
Awata, N .
CIRCULATION, 1999, 100 (01) :21-26
[6]
Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT).[J].Hideo Tamai;Osamu Katoh;Shin Suzuki;Kenshi Fujii;Tadanori Aizawa;Shin-ichi Takase;Hiroyuki Kurogane;Hideo Nishikawa;Takahito Sone;Kazuyoshi Sakai;Takahiko Suzuki.American Heart Journal.1999, 5
[7]
Impact of cilostazol on intimal proliferation after directional coronary atherectomy [J].
Tsuchikane, E ;
Katoh, O ;
Sumitsuji, S ;
Fukuhara, A ;
Funamoto, M ;
Otsuji, S ;
Tateyama, H ;
Awata, N ;
Kobayashi, T .
AMERICAN HEART JOURNAL, 1998, 135 (03) :495-502
[8]
A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation [J].
Kunishima, T ;
Musha, H ;
Eto, F ;
Iwasaki, T ;
Nagashima, J ;
Masui, Y ;
So, T ;
Nakamura, T ;
Oohama, N ;
Murayama, M .
CLINICAL THERAPEUTICS, 1997, 19 (05) :1058-1066
[9]
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial [J].
Yokoi, H ;
Daida, H ;
Kuwabara, Y ;
Nishikawa, H ;
Takatsu, F ;
Tomihara, H ;
Nakata, Y ;
Kutsumi, Y ;
Ohshima, S ;
Nishiyama, S ;
Seki, A ;
Kato, K ;
Nishimura, S ;
Kanoh, T ;
Yamaguchi, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) :855-862
[10]
Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty [J].
OKeefe, JH ;
Stone, GW ;
McCallister, BD ;
Maddex, C ;
Ligon, R ;
Kacich, RL ;
Kahn, J ;
Cavero, PG ;
Hartzler, GO ;
McCallister, BD .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (08) :649-&